Literature DB >> 15519647

Silent non-alcoholic fatty liver disease-a clinical-histological study.

Paolo Sorrentino1, Giovanni Tarantino, Paolo Conca, Alessandro Perrella, Maria Luigi Terracciano, Raffaella Vecchione, Giovanna Gargiulo, Nicola Gennarelli, Roberto Lobello.   

Abstract

BACKGROUND/AIMS: We studied the prevalence of non-alcoholic fatty liver disease and non-alcoholic-steatohepatitis in patients with metabolic-syndrome but normal liver enzymes. The histological findings of patients with normal liver enzymes and non-alcoholic-steatohepatitis were compared with those of a control-group with persistently abnormal liver enzymes.
METHODS: Patients presenting with normal liver enzymes were enrolled in the study and underwent liver biopsy. Prevalence of non-alcoholic-steatohepatitis and risk factors for fibrosis and cirrhosis were evaluated. Data from a control-group with non-alcoholic-steatohepatitis and abnormal liver enzymes were used to compare the histological findings.
RESULTS: Fifty-eight of the 80 patients enrolled had varying degrees of non-alcoholic steatohepatitis, of these 26 had fibrosis and 8 silent cirrhosis. The association of metabolic-syndrome, female-sex, a long-history of obesity and body mass index>45 were considered to be independent risk-factors for fibrosis. Comparing the histological findings of cases and controls we found a similar severity of steatosis and fibrosis, with a greater prevalence of ballooning degeneration and glycogenated-nuclei rather than lobular-inflammation.
CONCLUSIONS: In the subjects selected according to our criteria, liver enzyme levels could not be used as surrogate markers of non-alcoholic-steatohepatitis. Histological hallmarks of patients with metabolic-syndrome, normal liver enzymes and non-alcoholic-steatohepatitis consist to a lesser degree of lobular-inflammation and a more severe ballooning and glycogenated-nuclei.

Entities:  

Mesh:

Year:  2004        PMID: 15519647     DOI: 10.1016/j.jhep.2004.07.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  47 in total

1.  NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis.

Authors:  Tarsila Ribeireiro; James Swain; Michael Sarr; Michael Kendrick; Florencia Que; Schuyler Sanderson; Anuradha Krishnan; Kimberly Viker; Kymberly Watt; Michael Charlton
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

Review 2.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

3.  A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients.

Authors:  Alex Ulitsky; Ashwin N Ananthakrishnan; Richard Komorowski; James Wallace; Sri Naveen Surapaneni; Jose Franco; Kia Saeian; Samer Gawrieh
Journal:  Obes Surg       Date:  2010-06       Impact factor: 4.129

4.  Is there any progress in the treatment of non-alcoholic fatty liver disease?

Authors:  Emmanuel A Tsochatzis; George V Papatheodoridis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-02-06

5.  Factors associated with significant liver fibrosis assessed using transient elastography in general population.

Authors:  Seng Chan You; Kwang Joon Kim; Seung Up Kim; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Won Jae Lee; Kwang-Hyub Han
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 6.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.

Authors:  Qing Pang; Jing-Yao Zhang; Si-Dong Song; Kai Qu; Xin-Sen Xu; Su-Shun Liu; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

7.  The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease.

Authors:  Phunchai Charatcharoenwitthaya; Keith D Lindor; Paul Angulo
Journal:  Dig Dis Sci       Date:  2012-02-29       Impact factor: 3.199

Review 8.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

Review 9.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 10.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.